Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 48 of 48 entries
View as:

REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis

Phase: N/A Priority: Normal
NCT ID: NCT06315010 Org: User:
Start: 06/30/25 End: 04/30/28 Due: 04/30/29

A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single Agent

Phase: N/A Priority: Normal
NCT ID: NCT03367689 Org: User:
Start: 04/17/18 End: 12/31/21 Due: 12/31/22

Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients with Active Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT06676917 Org: User:
Start: 04/30/25 End: 08/31/27 Due: 08/31/28

T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02562378 Org: User:
Start: 10/31/15 End: 12/31/18 Due: 12/31/19

Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS)

Phase: N/A Priority: Normal
NCT ID: NCT04231981 Org: User:
Start: 04/28/20 End: 08/26/22 Due: 08/26/23

Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment

Phase: N/A Priority: Normal
NCT ID: NCT02061085 Org: User:
Start: 07/31/13 End: 12/31/15 Due: 12/31/16

Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 -

Phase: N/A Priority: Normal
NCT ID: NCT03819010 Org: User:
Start: 05/07/19 End: 12/31/19 Due: 12/31/20

DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease

Phase: N/A Priority: Normal
NCT ID: NCT04420598 Org: User:
Start: 05/25/20 End: 04/04/23 Due: 04/04/24

Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06604858 Org: User:
Start: 05/29/25 End: 10/31/26 Due: 10/31/27

Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT03795012 Org: User:
Start: 04/30/19 End: 03/31/21 Due: 03/31/22

PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)

Phase: N/A Priority: Normal
NCT ID: NCT03809988 Org: User:
Start: 04/05/19 End: 11/30/22 Due: 11/30/23

Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT03328884 Org: User:
Start: 05/02/17 End: 04/02/25 Due: 04/02/26

Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04464174 Org: User:
Start: 10/08/20 End: 11/10/23 Due: 11/10/24

Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02491983 Org: User:
Start: 08/31/15 End: 01/31/20 Due: 01/31/21

Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients

Phase: N/A Priority: Normal
NCT ID: NCT04300790 Org: User:
Start: 10/23/20 End: 03/16/25 Due: 03/16/26

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

Phase: N/A Priority: Normal
NCT ID: NCT06382948 Org: User:
Start: 12/05/24 End: 04/30/28 Due: 04/30/29

Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.

Phase: N/A Priority: Normal
NCT ID: NCT03161353 Org: User:
Start: 06/26/17 End: 11/01/26 Due: 11/01/27

Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%

Phase: N/A Priority: Normal
NCT ID: NCT05659563 Org: User:
Start: 07/20/23 End: 01/30/25 Due: 01/30/26

ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL

Phase: N/A Priority: Normal
NCT ID: NCT04603183 Org: User:
Start: 06/02/21 End: 06/30/25 Due: 06/30/26

Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06612203 Org: User:
Start: 01/17/25 End: 10/31/27 Due: 10/31/28

A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population

Phase: N/A Priority: Normal
NCT ID: NCT05708235 Org: User:
Start: 04/01/24 End: 12/30/28 Due: 12/30/29

Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

Phase: N/A Priority: Normal
NCT ID: NCT06486883 Org: User:
Start: 05/31/25 End: 01/31/28 Due: 01/31/29

T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT06048718 Org: User:
Start: 06/05/24 End: 07/31/26 Due: 07/31/27